Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 6/20 | 0.53 |
| ▸ | F12 | P00748 | 1/20 | 0.77 |
| ▸ | PLAU | P00749 | 15/20 | 0.57 |
| ▸ | PLG | P00747 | 8/20 | 0.53 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.53 |
| ▸ | KLK1 | P06870 | 2/20 | 0.53 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.52 |
| ▸ | PLAT | P00750 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29568370 | 1.00 | F12 (0.77) | F12PLAUPLGKLKB1PRSS1 | |
| SCHEMBL29934139 | 1.00 | F12 (0.77) | F12PLAUPLGKLKB1PRSS1 | |
| SCHEMBL29568530 | 0.88 | F12 (1.00) | F12PLAUPLGKLKB1PRSS1 | |
| SCHEMBL3301671 | 0.88 | F12 (1.00) | F12PLAUPLGKLKB1PRSS1 | |
| SCHEMBL31499215 | 0.88 | F12 (1.00) | F12PLAUPLGKLKB1PRSS1 | |
| Hydrochloric Acid SCHEMBL7837112 | 0.86 | F12 (0.96) | F12PLAUPLGKLKB1PRSS1 | |
| SCHEMBL10938172 | 0.77 | FTO (0.66) | F12PLAUPLGKLKB1PRSS1 | |
| SCHEMBL31266874 | 0.75 | FTO (0.54) | F12PLAUPLGKLKB1PRSS1 | |
| SCHEMBL7342007 | 0.75 | FTO (0.54) | F12PLAUPLGKLKB1PRSS1 | |
| SCHEMBL7338895 | 0.75 | NSD2 (0.45) | F12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504499-A | Synthesis method of 6-amidino-2-naphthol mesylate | 江苏杜瑞制药有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119390614-A | Preparation method of nafamostat mesylate | 河北广祥制药有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-119143634-A | Preparation method of nafamostat mesylate | 北京诺康达医药科技股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| CN-117185963-A | Preparation method of high-purity nafamostat mesylate | 华仁药业（日照）有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-116479485-B | High-reliability lead frame and preparation method thereof | 泰州东田电子有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-116479485-A | High-reliability lead frame and preparation method thereof | 泰州东田电子有限公司 | 2023-07-25 | — | — | CN | claimed |
| WO-2022164150-A1 | NAFAMOSTAT MESYLATE AND METHOD FOR PRODUCING INTERMEDIATE THEREOF | (주)국전약품 | 2022-08-04 | — | — | WO | claimed |
| CN-110330447-B | Preparation method and application of nafamostat mesylate intermediate | 北京赛升药业股份有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-102225903-B | Amidino guanido substituted aromatic heterocyclic copmound and synthesis and use thereof | REN JIANDONG | 2014-11-26 | — | — | CN | claimed |
| US-4777182-A | ENZYME, HORMONE, COMPLEMENT INHIBITORS | TORII & CO., LTD. (JP) | 1988-10-11 | — | — | US | claimed |
| CN-121471113-A | Nafamostat medium Process for the preparation of intermediates | 鲁南制药集团股份有限公司 | 2026-02-06 | — | — | CN | disclosed |
| CN-119390614-B | Preparation method of nafamostat mesylate | 河北广祥制药有限公司 | 2025-09-19 | — | — | CN | disclosed |
| US-20250188022-A1 | PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2025-06-12 | — | — | US | disclosed |
| CN-119504499-A | Synthesis method of 6-amidino-2-naphthol mesylate | 江苏杜瑞制药有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119504499-A | Synthesis method of 6-amidino-2-naphthol mesylate | 江苏杜瑞制药有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-4563527-A | INHIBITORS OF TRYPSIN, PLASMIN, KALLIKREIN, THROMBIN AND COMPLEMENT | TORII & CO., LTD. (JP) | 1986-01-07 | — | — | US | disclosed |
| US-4532255-A | Amidine compounds and anticomplement agent comprising same | TORII & CO., LTD. (JP) | 1985-07-30 | — | — | US | disclosed |
| US-4496584-A | ANTITRYPSIN, ANTIKALLIKREIN, ANTITHROMBIN OR ANTIPLASMIN AGENT | TORII & CO. LTD. (JP) | 1985-01-29 | — | — | US | disclosed |
| US-4454338-A | 6-AMIDINO-2-NATHTHYL-4-GUANIDINOBENZOATE | TORII & CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| EP-0048433-A2 | Novel amidine compounds, process for producing same and anti-complement agent comprising them | TORII & CO., LTD. (JP) | 1982-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188022-A1 | PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES | TPMT, ADH1C, ADH1A | F2 1213/4885F12 925/4885PLAU 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.